<DOC>
	<DOCNO>NCT01713426</DOCNO>
	<brief_summary>This study compare efficacy tolerability Qutenza pregabalin patient suffer peripheral neuropathic pain . Treatment allocation one treatments duration study 10 week ( assume screen treatment allocation take 2 week ) . Participants ask complete questionnaire various aspect relate condition throughout study . This study include subject suffer Postherpetic Neuralgia , Peripheral Nerve Injury Non Diabetic peripheral polyneuropathy .</brief_summary>
	<brief_title>A Study Compare QUTENZA With Pregabalin Treatment Peripheral Neuropathic Pain ( PNP ) After 8 Weeks Treatment</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Peripheral Nerve Injuries</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>1 . Documented diagnosis probable definite PNP 2 . Localized welldefined area PNP , suitable treatment QUTENZA 3 . Documented diagnosis Baseline Visit either : Postherpetic neuralgia ( PHN ) pain persist least 6 month since shingle vesicle crust Peripheral nerve injury ( PNI ) include postsurgical posttraumatic neuropathic pain , persist minimum 3 month Nondiabetic painful peripheral polyneuropathy pain persist minimum 3 month , include ( ) smallfiber neuropathy , confirm quantitative sensory testing ( QST ) , laser evoke potential ( LEP ) skin biopsy , ( ii ) chemotherapy induce neuropathy subject stable neoplastic disease , ( iii ) , adequately characterize painful peripheral polyneuropathy , base clinical history examination 4 . Average pain score ≥4 Screening Period , minimum least 4 consecutive day ( use `` average pain past 24 hour '' Numeric Pain Rating Scale ( NPRS ) score 5 . Intact , nonirritated , dry skin painful area ( ) treat 6 . Is either : Naïve treatment pregabalin gabapentin , OR In opinion investigator , receive adequate trial treatment pregabalin gabapentin 7 . Subject willing receive pregabalin QUTENZA part trial 8 . Females child bear potential must willing use highly effective method birth control study 30 day follow study termination 1 . Significant ongoing recurrent pain etiology PHN , PNI nondiabetic painful peripheral polyneuropathy , example : compressionrelated neuropathy ( e.g . spinal stenosis ) , radiculopathy , tumorrelated pain , fibromyalgia arthritis 2 . Complex Regional Pain Syndrome ( CRPS , Type I II ) 3 . Neuropathic pain relate previously administer radiotherapy , diabetes mellitus HIVAN 4 . Neuropathic pain area locate face , hairline scalp , and/or proximity mucous membrane 5 . Severe loss heat sensation painful area , indicative Cfiber denervation 6 . Reported daily pain score 10 NPRS least 4 day Screening Period 7 . Past current history diabetes mellitus 8 . Unstable poorly control hypertension recent history cardiovascular event , opinion investigator , would put subject risk adverse cardiovascular reaction relate patch application procedure 9 . Creatinine clearance ( CLcr ) &lt; 60mL/min accord CockcroftGault formula 10 . Untreated ongoing generalize anxiety disorder accord DSMIV ICD10 criteria 11 . Severe ongoing depression accord DSMIV ICD10 criteria 12 . Evidence cognitive impairment include dementia may interfere subject 's ability complete study evaluation recall pain level past 24 hour 13 . Planned elective surgery trial 14 . Changes stable neuropathic pain background medication 4 week prior Baseline Visit 15 . Any prior receipt QUTENZA patch , include blind patch administer part clinical trial 16 . Hypersensitivity capsaicin ( i.e. , chilli pepper Overthecounter [ OTC ] capsaicin product ) , QUTENZA excipients , local anesthetic , adhesives 17 . Treatment pregabalin gabapentin within 2 month prior Baseline Visit 18 . Hypersensitivity pregabalin excipients 19 . Use opioids exceed total daily dose morphine 200 mg/day , equivalent ; intravenous opioids tapentadol , regardless dose , within 7 day precede Baseline Visit 20 . Use topical pain medication , nonsteroidal antiinflammatory drug , menthol , methyl salicylate , local anesthetic ( include patch contain lidocaine ) , steroid capsaicin product painful area treat within 7 day precede Baseline Visit 21 . Chemotherapy within 3 month Baseline Visit , except maintenance hormone treatment 22 . Use investigational agent within 30 day prior Baseline Visit 23 . Active substance abuse history chronic substance abuse within 1 year prior screening ; prior chronic substance abuse ( include alcoholism ) likely reoccur study period judge investigator 24 . Female subject childbearing potential positive serum urine pregnancy test prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Post herpetic neuralgia</keyword>
	<keyword>Peripheral Neuropathic Pain</keyword>
	<keyword>Qutenza</keyword>
	<keyword>Pregabalin</keyword>
	<keyword>NGX-4010</keyword>
</DOC>